Here are the 10-K annual reports from Rocket Pharmaceuticals, Inc. Warrant (RCKTW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RCKTW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCKTW filings page.
Rocket Pharmaceuticals is a late-stage biotech company developing gene therapies for rare, often fatal genetic diseases, with a strategic focus on inherited cardiomyopathies. It runs both AAV and lentiviral platforms and operates a large cGMP manufacturing facility in Cranbury, New Jersey.
In 2025 Rocket implemented a corporate reorganization, including a workforce reduction of about 30% and cost-saving initiatives expected to lower 12‑month operating expenses by roughly 25%, to extend its cash runway and concentrate resources on its AAV cardiovascular pipeline. Development of Fanconi anemia and pyruvate kinase deficiency programs is being de‑prioritized while the company explores partnerships.
Lead programs include RP‑A501 for Danon disease, where positive long‑term Phase 1 data supported a pivotal Phase 2 trial that was temporarily paused after two serious adverse events, including one death, then allowed to resume at a lower dose with added safeguards. RP‑A601 for PKP2‑related arrhythmogenic cardiomyopathy has early Phase 1 data showing tolerability and increased PKP2 expression, and RP‑A701 for BAG3‑related dilated cardiomyopathy entered Phase 1 after FDA IND clearance and Fast Track designation.
In hematology, ex vivo gene therapy KRESLADI for severe LAD‑I has published long‑term data and a resubmitted BLA with a new PDUFA date of March 28, 2026. Across programs, Rocket highlights extensive regulatory designations, complex licensing arrangements, and a wide array of risks, including ongoing losses, financing needs, clinical and regulatory uncertainty, manufacturing and data‑privacy obligations, intense competition, and protection of its intellectual property.